HODGKIN'S LYMPHOMA
Clinical trials for HODGKIN'S LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new HODGKIN'S LYMPHOMA trials appear
Sign up with your email to follow new studies for HODGKIN'S LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug XmAb20717 tested in rare cancers – trial suspended
Disease control TerminatedThis phase II trial tests the safety and effectiveness of a drug called XmAb20717 in 140 people with advanced rare cancers, including mesothelioma, lymphoma, and small cell lung cancer. The drug is given by IV. The main goal is to see if tumors shrink. The trial is currently susp…
Matched conditions: HODGKIN'S LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphoma
Disease control OngoingThis early-phase study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. Researchers take a patient's own immune cells (T cells), add a special receptor that targets the CD30 protein found on lymphoma cel…
Matched conditions: HODGKIN'S LYMPHOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Talking it out: study tests if doctor training eases cancer Survivors' transition
Knowledge-focused OngoingThis study looks at whether training doctors in communication skills can help lymphoma patients move from active treatment to survivorship. It involves 314 patients with Hodgkin's or Diffuse Large B-cell Lymphoma. The goal is to see if better conversations with their doctors impr…
Matched conditions: HODGKIN'S LYMPHOMA
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC